The Drug-Induced Respiratory Disease Website
Publications
ALK-rearranged lung adenocarcinoma patient with development of severe sinus bradycardia after treatment with crizotinib: A case report.
Medicine 2019 Mar;98;e14826 — 2019 Mar — e14826
Severe bradycardia associated with crizotinib.
Postgraduate medical journal 2017 12;93;774-775 — 2017 12 — 774-775
Cappuzzo F, Moro-Sibilot D, Gautschi O, Boleti E, Felip E, Groen HJ, Germonpré P, Meldgaard P, Arriola E, Steele N, Fox J, Schnell P, Engelsberg A, Wolf J
Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: an expert consensus.
Lung cancer (Amsterdam, Netherlands) 2015 Feb;87;89-95 — 2015 Feb — 89-95
Girard N, Audigier-Valette C, Cortot AB, Mennecier B, Debieuvre D, Planchard D, Zalcman G, Moro-Sibilot D, Cadranel J, Barlési F
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Expert review of anticancer therapy 2015 Feb;15;225-33 — 2015 Feb — 225-33
Asymptomatic profound sinus bradycardia (heart rate ?45) in non-small cell lung cancer patients treated with crizotinib.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2011 Dec;6;2135-7 — 2011 Dec — 2135-7